A Phase I/IIa Multi-dose Escalation Study of BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 05 Sep 2017
At a glance
- Drugs Indatuximab ravtansine (Primary) ; Dexamethasone; Lenalidomide; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Biotest Pharmaceuticals
- 31 Aug 2017 Planned End Date changed from 1 Nov 2017 to 1 Nov 2018.
- 31 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.
- 30 Jan 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History